

# Oklahoma Health Care Authority

## Drug Utilization Review Board

### (DUR Board)

Meeting – November 9, 2022 @ 4:00pm

at the

Oklahoma Health Care Authority (OHCA)

4345 N. Lincoln Blvd.

Oklahoma City, Oklahoma 73105

**NOTE:** *The DUR Board will meet at 4:00pm at OHCA (see address above). There will be Zoom access to this meeting; however, Zoom access will be set up in view-only mode with no voting, speaking, video, or chat box privileges. Zoom access will allow for viewing of the presentation slides as well as audio of the presentations and discussion during the meeting; however, the DUR Board meeting will not be delayed or rescheduled due to any technical issues that may arise.*

### **AGENDA**

Discussion and action on the following items:

Items to be presented by Dr. Muchmore, Chairman:

#### **1. Call to Order**

A. Roll Call – Dr. Wilcox

#### **DUR Board Members:**

|                               |                         |
|-------------------------------|-------------------------|
| Dr. Jennifer de los Angeles – | participating in person |
| Ms. Jennifer Boyett –         | participating in person |
| Dr. Megan Hanner –            | participating in person |
| Dr. Lynn Mitchell –           | participating in person |
| Dr. John Muchmore –           | participating in person |
| Dr. Lee Muñoz –               | participating in person |
| Dr. James Osborne –           | participating in person |

#### **Viewing Access Only via Zoom:**

Please register for the meeting at:

[https://zoom.us/webinar/register/WN\\_73z8ERX7Sv-KeQGP3GVqPg](https://zoom.us/webinar/register/WN_73z8ERX7Sv-KeQGP3GVqPg)

After registering, you will receive a confirmation email containing information about joining the webinar.

Or join by phone:

Dial: +1-602-753-0140 or +1-669-219-2599

Webinar ID: 952 7560 1667

Passcode: 69395211

## **Public Comment for Meeting:**

- Speakers who wish to sign up for public comment at the OHCA DUR Board meeting may do so in writing by visiting the DUR Board page on the OHCA website at [www.oklahoma.gov/ohca/about/boards-and-committees/drug-utilization-review/dur-board](http://www.oklahoma.gov/ohca/about/boards-and-committees/drug-utilization-review/dur-board) and completing the [Speaker Registration Form](#). Completed Speaker Registration forms should be submitted to [DURPublicComment@okhca.org](mailto:DURPublicComment@okhca.org). Forms must be received after the DUR Board agenda has been posted and no later than 24 hours before the meeting.
- The DUR Board meeting will allow public comment and time will be limited to 40 minutes total for all speakers during the meeting. Each speaker will be given 5 minutes to speak at the public hearing. If more than 8 speakers properly request to speak, time will be divided evenly.
- Only 1 speaker per manufacturer will be allowed.
- Any speakers who sign up for public comment must attend the DUR Board meeting in person at OHCA (see above address). Public comment through Zoom will not be allowed for the DUR Board meeting.

Items to be presented by Dr. Muchmore, Chairman:

### **2. Public Comment Forum**

- A. Acknowledgement of Speakers for Public Comment

Items to be presented by Dr. Muchmore, Chairman:

### **3. Action Item – Approval of DUR Board Meeting Minutes – See Appendix A**

- A. October 12, 2022 DUR Board Meeting Minutes
- B. October 12, 2022 DUR Board Recommendations Memorandum
- C. Correspondence

Items to be presented by Dr. Chandler, Dr. O’Halloran, Dr. Muchmore, Chairman:

### **4. Update on Medication Coverage Authorization Unit/Impact of Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Modulators – See Appendix B**

- A. Pharmacy Help Desk Activity for October 2022
- B. Medication Coverage Activity for October 2022
- C. Impact of CFTR Modulators

Items to be presented by Dr. O’Halloran, Dr. Muchmore, Chairman:

### **5. Action Item – 2023 DUR Board Meeting Dates – See Appendix C**

- A. 2023 DUR Board Meeting Dates

Items to be presented by Dr. O’Halloran, Dr. Muchmore, Chairman:

### **6. Action Item – Vote to Prior Authorize Enjaymo™ (Sutimlimab-jome), Pyrukynd® (Mitapivat), and Zynteglo® (Betibeglogene Autotemcel) and Update the Approval Criteria for the Anemia Medications – See Appendix D**

- A. Market News and Updates

- B. Product Summaries
- C. College of Pharmacy Recommendations

Items to be presented by Dr. Wilson, Dr. Muchmore, Chairman:

**7. Action Item – Vote to Prior Authorize Sotyktu™ (Deucravacitinib), Spevigo® (Spesolimab-sbzo), and Tavneos® (Avacopan) and Update the Approval Criteria for the Targeted Immunomodulator Agents – See Appendix E**

- A. Market News and Updates
- B. Product Summaries
- C. College of Pharmacy Recommendations

Items to be presented by Dr. Kottoor, Dr. Muchmore, Chairman:

**8. Action Item – Vote to Prior Authorize Xenpozyme® (Olipudase Alfa-rpcp) – See Appendix F**

- A. Market News and Updates
- B. Xenpozyme® (Olipudase Alfa-rpcp) Product Summary
- C. College of Pharmacy Recommendations

Items to be presented by Dr. Borders, Dr. Muchmore, Chairman:

**9. Action Item – Vote to Prior Authorize Besremi® (Ropeginterferon Alfa-2b-njft) and Vonjo™ (Pacritinib) – See Appendix G**

- A. Market News and Updates
- B. Product Summaries
- C. College of Pharmacy Recommendations

Items to be presented by Dr. Chandler, Dr. Muchmore, Chairman:

**10. Action Item – Annual Review of Imcivree™ (Setmelanotide) – See Appendix H**

- A. Current Prior Authorization Criteria
- B. Utilization of Imcivree™ (Setmelanotide)
- C. Prior Authorization of Imcivree™ (Setmelanotide)
- D. Market News and Updates
- E. College of Pharmacy Recommendations

Items to be presented by Dr. Wilson, Dr. Muchmore, Chairman:

**11. Action Item – Annual Review of Lambert-Eaton Myasthenic Syndrome (LEMS) Medications – See Appendix I**

- A. Current Prior Authorization Criteria
- B. Utilization of LEMS Medications
- C. Prior Authorization of LEMS Medications
- D. Market News and Updates
- E. College of Pharmacy Recommendations
- F. Utilization Details of LEMS Medications

Items to be presented by Dr. Kottoor, Dr. Muchmore, Chairman:

**12. Action Item – Annual Review of Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor Medications – See Appendix J**

- A. Current Prior Authorization Criteria
- B. Utilization of VMAT2 Inhibitor Medications
- C. Prior Authorization of VMAT2 Inhibitor Medications
- D. Market News and Updates
- E. College of Pharmacy Recommendations
- F. Utilization Details of VMAT2 Inhibitor Medications

Items to be presented by Dr. Borders, Dr. Muchmore, Chairman:

**13. Annual Review of Multiple Myeloma Medications and 30-Day Notice to Prior Authorize Carvykti™ (Ciltacabtagene Autoleucel) and Tecvayli™ (Teclistamab-cqyv) – See Appendix K**

- A. Introduction
- B. Current Prior Authorization Criteria
- C. Utilization of Multiple Myeloma Medications
- D. Prior Authorization of Multiple Myeloma Medications
- E. Market News and Updates
- F. Product Summaries
- G. College of Pharmacy Recommendations
- H. Utilization Details of Multiple Myeloma Medications

Items to be presented by Dr. O'Halloran, Dr. Muchmore, Chairman:

**14. Annual Review of Asthma and Chronic Obstructive Pulmonary Disease (COPD) Maintenance Medications and 30-Day Notice to Prior Authorize Tezspire® (Tezepelumab-ekko) – See Appendix L**

- A. Current Prior Authorization Criteria
- B. Utilization of Asthma and COPD Maintenance Medications
- C. Prior Authorization of Asthma and COPD Maintenance Medications
- D. Market News and Updates
- E. Tezspire® (Tezepelumab-ekko) Product Summary
- F. College of Pharmacy Recommendations
- G. Utilization Details of Asthma and COPD Maintenance Medications
- H. Utilization Details of Asthma-Indicated Monoclonal Antibodies

Items to be presented by Dr. Wilson, Dr. Muchmore, Chairman:

**15. Annual Review of Atopic Dermatitis (AD) Medications and 30-Day Notice to Prior Authorize Adbry™ (Tralokinumab-ldrm) and Cibinqo™ (Abrocitinib) – See Appendix M**

- A. Current Prior Authorization Criteria
- B. Utilization of AD Medications
- C. Prior Authorization of AD Medications
- D. Market News and Updates
- E. Product Summaries

- F. Cost Comparison
- G. College of Pharmacy Recommendations
- H. Utilization Details of AD Medications

Items to be presented by Dr. Moss, Dr. Muchmore, Chairman:

**16. 30-Day Notice to Prior Authorize Skysona® (Elivaldogene Autotemcel) – See Appendix N**

- A. Introduction
- B. Skysona® (Elivaldogene Autotemcel) Product Summary
- C. College of Pharmacy Recommendations

Items to be presented by Dr. Chandler, Dr. Muchmore, Chairman:

**17. U.S. Food and Drug Administration (FDA) and Drug Enforcement Administration (DEA) Updates – See Appendix O**

Items to be presented by Dr. Adams, Dr. Muchmore, Chairman:

**18. Future Business\* (Upcoming Product and Class Reviews)**

- A. Anticoagulants and Platelet Aggregation Inhibitors
- B. Antidepressants
- C. Crohn’s Disease and Ulcerative Colitis (UC) Medications
- D. Skin Cancer Medications

\*Future product and class reviews subject to change.

**19. Adjournment**

NOTE: An analysis of the atypical [Aged, Blind, and Disabled (ABD)] patient subgroup of the Oklahoma Medicaid population has been performed pertaining to all recommendations included in this DUR Board meeting packet to ensure fair and knowledgeable deliberation of the potential impact of the recommendations on this patient population.